Secondary cytoreductive surgery for recurrent ovarian cancer improves overall survival - BJMO
Design of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian... | Download Scientific Diagram
Design of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian... | Download Scientific Diagram
Clinical Conundrums: Choosing the Best Management Approaches in Patients With Ovarian Cancer Thomas J. Herzog, MD Director, Division of Gynecologic Oncology. - ppt download
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort | British Journal of Cancer
A trial looking at surgery for ovarian cancer that has come back (DESKTOP 3, ENGOT ov20) | Cancer Research UK
Targeted Therapy in Ovarian Cancer | Published in healthbook TIMES Oncology Hematology
Cancers | Free Full-Text | Investigating the Impact of Ultra-Radical Surgery on Survival in Advanced Ovarian Cancer Using Population-Based Data in a Multicentre UK Study
Study schema. CR, complete response; OS, overall survival; PD,... | Download Scientific Diagram
![PDF] A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/9f70a61bd62289d61bdc1f3b559d831e3bc47919/4-Figure1-1.png "PDF] A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study | Semantic Scholar")
PDF] A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study | Semantic Scholar
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
ESGO on X: "👋 Ready for the next #ENYGO webinar? Register now for our webinar with Andreas du Bois. He'll talk about DESKTOP III Trial Results: Do patients in recurrent ovarian cancer
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent #ovariancancer - DESKTOP III and SOC -1 #ASCO20 # - Thread from Shannon Westin @ShannonWestin - Rattibha
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer | NEJM
The systemic treatment of recurrent ovarian cancer revisited - ScienceDirect
Shannon Westin, MD, MPH, FASCO on X: "This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent # ovariancancer - DESKTOP III and SOC -1 #ASCO20 #SGOatASCO #gyncsm https://t.co/pHGWklYWKs" /
Table 4 from Surgical management of recurrent ovarian cancer. | Semantic Scholar
Cancers | Free Full-Text | Surgery in Recurrent Ovarian Cancer: A Meta-Analysis
Journal of Gynecologic Oncology
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
Advances in ovarian cancer, from biology to treatment | Nature Cancer
